Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

De novo genome assembly of the fungal plant pathogen Pyrenophora semeniperda.

Soliai MM, Meyer SE, Udall JA, Elzinga DE, Hermansen RA, Bodily PM, Hart AA, Coleman CE.

PLoS One. 2014 Jan 27;9(1):e87045. doi: 10.1371/journal.pone.0087045. eCollection 2014.

2.

Most lung and colon cancer susceptibility genes are pair-wise linked in mice, humans and rats.

Quan L, Stassen AP, Ruivenkamp CA, van Wezel T, Fijneman RJ, Hutson A, Kakarlapudi N, Hart AA, Demant P.

PLoS One. 2011 Feb 24;6(2):e14727. doi: 10.1371/journal.pone.0014727.

3.

Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.

Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Wárlám-Rodenhuis CC, Bartelink H.

J Clin Oncol. 2009 Oct 20;27(30):4939-47. doi: 10.1200/JCO.2008.21.5764. Epub 2009 Aug 31.

4.

Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.

Zuur CL, Simis YJ, Lamers EA, Hart AA, Dreschler WA, Balm AJ, Rasch CR.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):490-6. doi: 10.1016/j.ijrobp.2008.08.011. Epub 2009 Jan 8.

PMID:
19135315
5.

Secondary intention healing after excision of nonmelanoma skin cancer of the head and neck: statistical evaluation of prognostic values of wound characteristics and final cosmetic results.

van der Eerden PA, Lohuis PJ, Hart AA, Mulder WC, Vuyk H.

Plast Reconstr Surg. 2008 Dec;122(6):1747-55. doi: 10.1097/PRS.0b013e31818a9aaa.

PMID:
19050527
6.

Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.

Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG.

Neuroendocrinology. 2009;89(3):296-301. doi: 10.1159/000162876. Epub 2008 Oct 7.

PMID:
18840995
7.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.

Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26.

PMID:
18819002
8.

Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.

Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, van de Rijn M, Linn SC.

Am J Surg Pathol. 2008 Oct;32(10):1513-22. doi: 10.1097/PAS.0b013e31817a909a.

PMID:
18708938
9.

Evaluating clinical accuracy of continuous glucose monitoring devices: other methods.

Wentholt IM, Hart AA, Hoekstra JB, DeVries JH.

Curr Diabetes Rev. 2008 Aug;4(3):200-6. Review.

PMID:
18690901
10.

PRAME expression and clinical outcome of breast cancer.

Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R.

Br J Cancer. 2008 Aug 5;99(3):398-403. doi: 10.1038/sj.bjc.6604494. Epub 2008 Jul 22.

11.

No apparent local effect of insulin on microdialysis continuous glucose- monitoring measurements.

Hermanides J, Wentholt IM, Hart AA, Hoekstra JB, DeVries JH.

Diabetes Care. 2008 Jun;31(6):1120-2. doi: 10.2337/dc08-0145. Epub 2008 Mar 10.

PMID:
18332157
12.

How to assess and compare the accuracy of continuous glucose monitors?

Wentholt IM, Hart AA, Hoekstra JB, Devries JH.

Diabetes Technol Ther. 2008 Apr;10(2):57-68. doi: 10.1089/dia.2007.0216. Review.

PMID:
18260769
13.

Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up.

Kreike B, Hart AA, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver MJ.

Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1014-21. doi: 10.1016/j.ijrobp.2007.11.029. Epub 2008 Jan 30.

PMID:
18234444
14.

Goblet cell carcinoid of the appendix: a specific type of carcinoma.

van Eeden S, Offerhaus GJ, Hart AA, Boerrigter L, Nederlof PM, Porter E, van Velthuysen ML.

Histopathology. 2007 Dec;51(6):763-73.

PMID:
18042066
15.

Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.

Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.

J Clin Oncol. 2007 Aug 20;25(24):3759-65.

PMID:
17704425
16.

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC.

Cancer Chemother Pharmacol. 2008 May;61(6):1075-81. Epub 2007 Jul 18.

17.

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer.

Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, Jaspers MW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron HN, van Leeuwen FE.

JAMA. 2007 Jun 27;297(24):2705-15.

PMID:
17595271
18.

Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.

Kaas R, Muller SH, Hart AA, Rutgers EJ.

Eur J Surg Oncol. 2008 May;34(5):501-7. Epub 2007 Jun 6.

PMID:
17555911
19.

Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited.

Wentholt IM, Hart AA, Hoekstra JB, Devries JH.

Diabetes Technol Ther. 2007 Apr;9(2):169-75.

PMID:
17425443
20.

Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.

Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1320-5. Epub 2007 Apr 6.

PMID:
17418969
21.

Late cardiotoxicity after treatment for Hodgkin lymphoma.

Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE.

Blood. 2007 Mar 1;109(5):1878-86. Epub 2006 Nov 21.

PMID:
17119114
22.

The psychological impact of annual chest X-ray follow-up in head and neck cancer.

Geurts TW, Ackerstaff AH, Van Zandwijk N, Hart AA, Hilgers FJ, Balm AJ.

Acta Otolaryngol. 2006 Dec;126(12):1315-20.

PMID:
17101594
23.

Predicting a local recurrence after breast-conserving therapy by gene expression profiling.

Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ, Bartelink H, Brown PO, Chang HY, van de Vijver MJ.

Breast Cancer Res. 2006;8(5):R62.

24.

Childhood white matter disorders: quantitative MR imaging and spectroscopy.

van der Voorn JP, Pouwels PJ, Hart AA, Serrarens J, Willemsen MA, Kremer HP, Barkhof F, van der Knaap MS.

Radiology. 2006 Nov;241(2):510-7.

PMID:
17057071
25.

The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls.

Kaas R, Kroger R, Peterse JL, Hart AA, Muller SH.

Eur Radiol. 2006 Dec;16(12):2842-8. Epub 2006 Aug 19.

PMID:
16924440
26.

Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling.

Peeters ST, Hoogeman MS, Heemsbergen WD, Hart AA, Koper PC, Lebesque JV.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):11-9. Epub 2006 Jun 6.

PMID:
16757129
27.

Prediction of poor outcome within the first 3 days of postanoxic coma.

Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, de Haan RJ; PROPAC Study Group.

Neurology. 2006 Jan 10;66(1):62-8. Erratum in: Neurology. 2006 Apr 11;66(7):1133.

PMID:
16401847
28.

Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients.

Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH.

Diabetes Care. 2005 Dec;28(12):2871-6.

PMID:
16306547
29.

Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation.

Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, De Jaeger K, Belderbos JS, Hart AA, Nowak PJ, van Herk M, Rasch CR.

Radiother Oncol. 2005 Nov;77(2):182-90. Epub 2005 Oct 26.

PMID:
16256231
30.

Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?

Geurts TW, Nederlof PM, van den Brekel MW, van't Veer LJ, de Jong D, Hart AA, van Zandwijk N, Klomp H, Balm AJ, van Velthuysen ML.

Clin Cancer Res. 2005 Sep 15;11(18):6608-14.

31.

Cross-validated Cox regression on microarray gene expression data.

van Houwelingen HC, Bruinsma T, Hart AA, Van't Veer LJ, Wessels LF.

Stat Med. 2006 Sep 30;25(18):3201-16.

PMID:
16143967
32.
33.

Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience.

Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AA, Horenblas S.

Eur Urol. 2005 Aug;48(2):239-45. Epub 2005 Apr 13.

PMID:
16005375
34.

Predictive value of neonatal MRI with respect to late MRI findings and clinical outcome. A study in infants with periventricular densities on neonatal ultrasound.

Sie LT, Hart AA, van Hof J, de Groot L, Lems W, Lafeber HN, Valk J, van der Knaap MS.

Neuropediatrics. 2005 Apr;36(2):78-89.

PMID:
15822020
35.

A protocol for building and evaluating predictors of disease state based on microarray data.

Wessels LF, Reinders MJ, Hart AA, Veenman CJ, Dai H, He YD, van't Veer LJ.

Bioinformatics. 2005 Oct 1;21(19):3755-62. Epub 2005 Apr 7.

PMID:
15817694
36.

Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience.

Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F.

J Gastrointest Surg. 2005 Feb;9(2):178-86.

PMID:
15694813
37.

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.

Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, Nieweg OE, de Gast GC.

Eur J Cancer. 2005 Feb;41(3):386-92.

PMID:
15691637
38.

The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.

Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J, Vecht ChJ.

Eur J Cancer. 2004 Dec;40(18):2726-33.

PMID:
15571954
40.

On cost effectiveness and sample size in clinical trials.

Hart AA, Dijkgraaf MG.

Pharmacoeconomics. 2004;22(10):685-8, author reply 688-9. No abstract available.

PMID:
15244493
41.

Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection.

van der Knaap MS, Vermeulen G, Barkhof F, Hart AA, Loeber JG, Weel JF.

Radiology. 2004 Feb;230(2):529-36. Erratum in: Radiology. 2004 May;231(2):605.

PMID:
14752192
42.

Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients.

Haas RL, Valdés-Olmos RA, Hoefnagel CA, Verheij M, de Jong D, Hart AA, Bartelink H.

Radiother Oncol. 2003 Dec;69(3):323-8.

PMID:
14644492
43.

Pseudomyxoma peritonei: a review of 62 cases.

van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA.

Eur J Surg Oncol. 2003 Oct;29(8):682-8.

PMID:
14511618
44.

Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.

Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ.

J Pathol. 2003 Sep;201(1):75-82.

PMID:
12950019
45.

Long-term effect of full-mouth tooth extraction on the responsiveness of peripheral blood monocytes.

Fokkema SJ, Loos BG, Hart AA, van der Velden U.

J Clin Periodontol. 2003 Aug;30(8):756-60.

PMID:
12887346
46.
47.

[The prevalence of use of restraints in a Dutch teaching hospital. An exploration in two wards].

Tutuarima JA, Semin-Goossens A, Hart AA, Sengkerij-Koolstra M.

Tijdschr Gerontol Geriatr. 2003 Jun;34(3):113-7. Dutch.

PMID:
12866253
48.

High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.

Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, Hart AA, van Oers MH, van der Hulst M, Baars JW, Bartelink H.

J Clin Oncol. 2003 Jul 1;21(13):2474-80.

PMID:
12829665
49.

Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy.

van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA.

Anticancer Res. 2003 Mar-Apr;23(2B):1501-8.

PMID:
12820416
50.

A comparison in cosmetic outcome between per-operative interstitial breast implants and delayed interstitial breast implants after external beam radiotherapy.

Pieters BR, Hart AA, Russell NS, Jansen EP, Peterse JL, Borger J, Rutgers EJ.

Radiother Oncol. 2003 May;67(2):159-64.

PMID:
12812845

Supplemental Content

Support Center